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Abstract
Genetic mapping studies have identified multiple cancer susceptibility regions at chromosome 8q24, upstream of the MYC
oncogene. MYC has been widely presumed as the regulated target gene, but definitive evidence functionally linking these
cancer regions with MYC has been difficult to obtain. Here we examined candidate functional variants of a haplotype block
at 8q24 encompassing the two independent risk alleles for prostate and breast cancer, rs620861 and rs13281615. We used
the mapping of DNase I hypersensitive sites as a tool to prioritise regions for further functional analysis. This approach
identified rs378854, which is in complete linkage disequilibrium (LD) with rs620861, as a novel functional prostate cancer-
specific genetic variant. We demonstrate that the risk allele (G) of rs378854 reduces binding of the transcription factor YY1
in vitro. This factor is known to repress global transcription in prostate cancer and is a candidate tumour suppressor.
Additional experiments showed that the YY1 binding site is occupied in vivo in prostate cancer, but not breast cancer cells,
consistent with the observed cancer-specific effects of this single nucleotide polymorphism (SNP). Using chromatin
conformation capture (3C) experiments, we found that the region surrounding rs378854 interacts with the MYC and PVT1
promoters. Moreover, expression of the PVT1 oncogene in normal prostate tissue increased with the presence of the risk
allele of rs378854, while expression of MYC was not affected. In conclusion, we identified a new functional prostate cancer
risk variant at the 8q24 locus, rs378854 allele G, that reduces binding of the YY1 protein and is associated with increased
expression of PVT1 located 0.5 Mb downstream.
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Introduction
Genome-wide association studies (GWAS) have identified
multiple independent cancer susceptibility loci upstream of the
MYC oncogene at chromosome 8q24 (reviewed in [1]): initial
studies revealed one breast [2], three prostate [3], one bladder
cancer [4] locus and one region conferring risk for multiple
cancers including prostate, colon and ovarian cancer. More
recently, a lymphocytic leukaemia [5] and five more prostate risk
regions have been identified [3,6,7]. The 8q24 region is currently
considered the most important susceptibility region for prostate
cancer, accounting for about 8% of the two-fold increase in risk
observed in first degree relatives [3]. MYC ranks as one of the most
consistently overexpressed genes comparing prostate tumours to
normal prostate tissue in a meta-analysis of five data sets [8],
indicating its importance in prostate cancer. Breast tumours and
metastatic prostate tumours carry frequent amplifications of the
8q24 region, spanning a large region covering both the MYC and
the neighbouring PVT1 gene [9,10]. Furthermore, both the MYC
and the PVT1 genes are frequent targets for retroviral integration
in mouse tumour assays [11]. The MYC oncogene functions as a
transcriptional activator, and is part of a complex regulatory
network controlling cell growth, apoptosis, differentiation and
other cellular responses [12]. PVT1 encodes a non-coding RNA
and is a host gene for several miRNAs, namely hsa-miR-1204,
1205, 1206 and 1207 [11,13]. The targets and function of PVT1
and its embedded miRNAs are still largely unknown.
The study presented here focuses on a haplotype block
containing a risk variant for prostate cancer (rs620861) [3] and a
second independent risk variant for breast cancer (rs13281615)
[2]. Other cancer risk loci at 8q24 have already been examined in
some detail. For example, the colorectal and prostate cancer
predisposition locus contains an enhancer that is able to interact
with theMYC gene and it was suggested that rs6983267 within this
enhancer alters a TCF7L2 (TCF4) binding site thus resulting in
changed sensitivity to WNT signalling [14,15]. Transgenic assays
indicate that rs6983267 increases expression of a reporter gene in
a pattern that mimics MYC activity in the mouse prostate [16].
Another prostate cancer-associated variant from the 8q24 region,
rs11986220, has been shown to form a FoxA1 site, leading to an
increased cancer risk because of stronger androgen responsiveness
[17]. However, when examining gene expression in primary
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human prostate and colon tissue samples, no correlation between
MYC expression and either of these SNPs was found [14,15,18,19],
but an allele-specific effect of rs6983267 was detectable in some
colorectal cancer cell lines [20].
The majority of cancer susceptibility loci identified by GWAS
do not affect coding regions of genes, and are thought to be
regulatory. However, the identification of functional SNPs has
been difficult since tagging SNPs employed in genetic mapping are
in tight LD with many SNPs, often covering large haplotype
blocks. In this study, we hypothesized that regulatory elements
affected by SNPs are likely to be positioned in regions of active
chromatin that are accessible for digestion by DNase I [21]. Thus,
we mapped DNase I hypersensitive sites (DHSs) as means of
prioritising regions for further functional analysis. Previously, this
approach successfully showed that the likely causative SNPs in
both the FGFR2 and TNRC9 susceptibility loci are in regions of
open chromatin [22,23]. Here, we find that rs378854, which is in
perfect LD with the prostate cancer risk SNP rs620861, maps to a
highly accessible site. We show that the cancer risk-associated
allele of rs378854 decreases binding of the transcription factor
YY1, activates in vitro expression of reporter constructs relative to
the non-risk allele, and increases expression of PVT1 in primary
normal human prostate tissue. Therefore, in addition to MYC, our
study implicates PVT1, located almost 0.5 Mb from the functional
variant, as a novel candidate cancer gene whose expression is
influenced by 8q24 genetic variation.
Results
The mapping of DHSs using DNase-seq in the breast cancer
cell line MCF-7 across the entire 8q24 cancer susceptibility region
revealed a prominent site of DNase I sensitivity within the
haplotype block that carries a breast and a prostate cancer
predisposition variant, rs13281615 and rs620861, respectively
(Figure 1A, Figure S1). The strength of the signal for the DHS
within this susceptibility block (S-DHS) is similar to that seen for
promoter regions of the FAM84B, MYC and PVT1 genes
(Figure 1A). In addition, a strong DHS was observed in a
conserved region 60kb upstream of the MYC gene (MYC-DHS).
The DNase-seq results were compared to results obtained in
DNase-chip experiments (Figure S2). All strong DHSs, for
example at the MYC promoter, were replicated. However, the S-
DHS which maps to a repetitive element could not be detected by
DNase-chip, as repetitive sequences are excluded from the array
by design. Interestingly, the same DNase-seq approach applied to
prostate cancer cell lines RWPE-1 and PC3 (Figure 1A) did not
detect a signal at the S-DHS location, suggesting that transcription
factor occupancy in this region may differ between breast and
prostate cancer cell lines. Signals at other locations, for example at
the MYC promoter are comparable in all three cell lines
(Figure 1A). Figure S3A shows an enlarged view of the region,
confirming that the S-DHS is in an open chromatin state in MCF-
7 cells, but in a closed state in two prostate cell lines. Despite being
located within a LINE element, the sequence of S-DHS is unique
enough to specifically align it to this genomic locus (see Figure S3
and S4 for details). To confirm that the open chromatin at the S-
DHS is indicative of the binding of regulatory nuclear proteins, we
examined chromatin immunoprecipitation data (ChIP-seq) for
MCF-7 cells [24]. Figure S5A and S5B show that S-DHS
sequences are bound by the two cohesin subunits Rad21 and SA1,
by CTCF and the transcription factor FoxA1, making it highly
likely that this region acts as a regulatory element in MCF-7 cells.
Sequence alignments for ChIP-seq, as for the DNase-seq, are
sufficiently specific to uniquely map the signals to this region.
Next, we analysed the 1.2 kb S-DHS region for the presence of
genetic variants that could be linked to variants previously
reported to be associated with breast or prostate cancer. The
1000 Genomes database included 12 SNPs, of which only 5 were
common (MAF .0.05) (Figure S2). Of these, rs378854 showed
complete LD (r2 = 1) with rs620861, the most strongly associated
prostate cancer SNP reported by Al Olama et al. [3] (indepen-
dently confirmed by Yeager et al. [6]), and also with rs445114,
reported in Gudmundsson et al. [7], while the other variants
displayed only low LD with this SNP. There was no strong
connection to breast cancer in this region, as rs378854 only ranks
as number 23 of all SNPs tested in this haplotype block [25].
Previous work and LD analysis of this region (Figure S6) supports
the presence of two independent functional variants within this
haplotype block, one for prostate cancer and one for breast cancer
[3,8]. Thus, we conclude that the closed state of chromatin within
the S-DHS might be associated with risk of prostate cancer,
through rs378854.
Motif prediction algorithms suggest that the minor, non-risk
allele (A) of rs378854 creates either a YY1 or a C/EBPa
transcription factor binding site. Using electrophoretic mobility
shift assays (EMSA) with nuclear extracts from breast and prostate
cancer cells (MCF-7 and PC3) we demonstrate that the
oligonucleotide probe overlapping rs378854 is able to interact
with several nuclear proteins (Figure 2A). The low mobility band
(black arrow) is not affected by the SNP. In contrast, the high
mobility band (red arrow) binds the minor allele more strongly in
both cell types. A third, more variable complex of intermediate
mobility is formed, which is not affected by the presence of the
SNP. The specificity of binding was confirmed by competition
assays with self, non-self and unrelated Oct-1 probe at different
concentrations (Figure 2A). Competition with known transcription
factor binding sites suggest that the high mobility band contains
the transcription factor YY1 (Figure 2B). This is confirmed by a
supershift observed after including a YY1 antibody in the reaction
(open red arrow, Figure 2C). The two upper complexes are
sensitive to excess SP1 probe (Figure 2B), but only one of these
complexes was supershifted by an SP1 antibody (black open arrow,
Figure 2C). SP1 and YY1 are known to interact physically and
function co-operatively to modify chromatin structure [26]. The
SP1 binding site may therefore be able to enhance the allelic
Author Summary
Genome-wide association studies have been very success-
ful at identifying gene loci that are associated with
common diseases. However for many of these it has been
very difficult to elucidate the identity and function of the
risk variant and how altered function predisposes to
disease. A 1.2-Mb gene-poor region upstream of the MYC
oncogene has been shown to contain at least 12 risk loci
associated with different types of cancer. In this study, we
use the analysis of chromatin conformation as a tool to
identify sub-regions within this 1.2 Mb region that are
involved in the control of gene expression, and we identify
molecular mechanisms which may confer risk of different
specific cancer types. In particular, we examine a risk locus
that is associated with predisposition to prostate cancer
and identify a DNA sequence variation that results in a
change in the binding site for the nuclear factor YY1 as a
potential causative mechanism. We show that the risk
locus is able to interact with two downstream genes, MYC
and PVT1, and present evidence that PVT1 is a candidate
new target gene regulated by the 8q24 risk region.
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Figure 1. Chromatin conformation at the 8q24 locus. (A) DNase-seq track for the breast cancer cell line MCF-7, the prostate cancer cell line PC3
and the normal-like prostate cell line RWPE-1 displayed on the UCSC genome browser for a 1.7 MB region (chr8: 127,550,000-129,250,000)
surrounding the 8q24 cancer susceptibility region, where peaks indicate regions of increased sensitivity to digestions with DNase I. Reads were
adjusted for the total number of reads in each experiment. DHSs and promoters used in subsequent analysis are marked by arrows. RefSeq genes are
shown, with L being LOC727677. The prostate and breast cancer susceptibility region is depicted by a horizontal red bar. Dotted lines show
interactions tested in the chromatin conformation capture experiment shown in (B). (B) Chromatin conformation capture (3C) experiment using the
S-DHS as bait in the HB2 breast and the RWPE-1 prostate cell lines. Target sequences are indicated above the lanes. A target sequence just upstream
of the EcoRI site 59 to the bait EcoRI site was used as ligation control (LC). Negative controls for each ligation reaction were cut but unligated DNA
fragments. The numbers below the panel refer to interactions shown in (A).
doi:10.1371/journal.pgen.1002165.g001
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differences caused by YY1 binding to SNP rs378854. Using
chromatin immunoprecipitation (ChIP) we also confirm that the
identified YY1 site is occupied in vivo in the prostate cancer cell line
1542-CP, but not in MCF-7 breast cancer cells (Figure 2E). In
1542-CP cells YY1 occupancy at rs378854 is higher than that
observed for a positive control fragment from the promoter region
of the glucocorticoid receptor, known to contain three indepen-
dent YY1 binding sites [27]. To test for allele-specific interaction
between YY1 and rs378854 in 1542-CP, we attempted an allele-
specific ChIP. Although there was an increase of binding towards
the A allele in the majority of experiments, the effect was small and
technical limitations prevent us from drawing definitive conclu-
sions from this experiment.
The S-DHS was identified in two breast cancer cell lines, T47
and MCF-7 (Figure S7). To examine the function of the S-DHS,
we cloned a 395 bp fragment central to the S-DHS encompassing
either the common (risk) or the minor (non-risk) allele of rs378854,
into the pGL3-basic, pGL3-promoter and pGL3-enhancer vectors
and assayed the ability of these allelic constructs to influence
transcription in transient reporter assays. In the prostate cancer
cell line PC3 the fragment containing the common (risk) allele has
moderate ability to activate transcription in the context of the
pGL3-enhancer construct, but for the minor allele there was
statistically significant evidence for repression of transcription in
the context of all constructs assayed (Figure 3). Our observation
are consistent with previous reports that YY1 can act as a potent
repressor of transcription [28]. In the breast cancer cell line MCF-
7, the minor (protective) allele again displayed lower transcrip-
tional activation than the common allele, but relative to the
parental construct no repression was observed (Figure 2E). When
the S-DHS was assayed in the pGL3-promoter vector the presence
of the minor versus the common SNP had no effect in MCF-7
cells. Thus, rs378854 showed cell-type specific allelic effects on
regulation of expression. The effect was evident in prostate cancer
PC3 cells, with significant repressor activity of the protective minor
allele. This may explain why rs378854 is associated with prostate,
but not breast cancer susceptibility.
The S-DHS maps to a 1.2 MB region with very few annotated
genes (Figure 1A). However, experiments for several 8q24
predisposition regions have indicated that this region is capable
of undergoing long-range chromatin looping [14,29]. We
therefore used chromatin conformation capture (3C) to examine
whether the DHS can physically interact with its neighbouring
genes,MYC, PVT1 and FAM84B. The pseudogene POU5F1P1 and
LOC727677 are not expressed in prostate cells at detectable levels
[17] and were therefore not included in this analysis. These
Figure 2. Protein DNA interactions at the sequences overlapping rs378854. (A) Electrophoretic mobility shift assays (EMSA) were carried
out with oligonucleotides containing the common (c) and minor (m) alleles of rs378854 and nuclear extracts from the breast cancer cell line MCF-7
and the prostate cancer cell line PC3. Competitor oligonucleotides were present at 100-, 30- and 10-fold excess for MCF-7 and 30-fold excess for PC3
and are indicated above the lanes. The red and black closed arrows denote the YY1 and SP1 complexes, respectively. (B) EMSAs of the
oligonucleotide containing the minor allele were carried out with PC3 nuclear extract and 30-fold excess of competitor oligonucleotides as shown. (C)
Supershift of the complex using polyclonal antibody against YY1, SP1, Oct-1 and C/EBPa with PC3 nuclear extracts. The red and black open arrows
denote the YY1 and SP1 supershift complexes. (D) An alignment of the two alleles with a YY1 binding site [28] is shown. (E) Chromatin
immunoprecipitation assay showing the fold-enrichment of the S-DHS and the positive control (glucocorticoid receptor, GR) sequences relative to a
negative control (S-DHS-ve) after immunoprecipitation with YY1 antibody in MCF-7 breast 1542-CP prostate cancer cells.
doi:10.1371/journal.pgen.1002165.g002
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Figure 3. Relative transcriptional activation by the common and minor alleles of rs378854. The 395 bp fragment overlapping the S-DHS
was cloned into pGL3-basic (pbas), pGL3-enhancer (pEnh) and pGL3-promoter (pPrm) and transcriptional activation of the reporter luciferase gene by
the two alleles (common and minor) assayed in the PC3 prostate cancer and the MCF-7 breast cancer cell lines. Activation by the insert is given
relative to the parental vector. Averages of six independent transfections are shown and the standard deviation for each data set is given in the bar
chart. Where significant, p-values are given for a Student’s t-test comparing the values obtained with common versus the minor allele in each vector
background.
doi:10.1371/journal.pgen.1002165.g003
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experiments showed that in both the normal-like breast cell line
HB2 and in the prostate cell line RWPE-1 the region surrounding
the S-DHS interacts with a DHS 60 kb upstream of the MYC gene
(MYC-DHS) and with the MYC and PVT1 promoters, located
360 kb, 420 kb and 480 kb 39 of the bait sequence, respectively
(Figure 1). Similar results were obtained in MCF-7 cells (data not
shown). There was no interaction with either the FAM84B
promoter or with a negative control sequence 400 kb 59 of the
DHS (Figure 1B). Our results suggest that in prostate cells both
MYC and PVT1 could be target genes of the S-DHS regulator
element. We note that both cohesin and CTCF also bind to the
MYC and PVT1 promoters in MCF-7 cells [24], suggesting a
mechanism by which an interaction may occur.
Expression of MYC has been analysed extensively in human
primary prostate and colon samples, but no correlation between its
expression and the genotype of six different risk SNPs was
identified [18,19]. In contrast, our study revealed that in a set of 59
normal prostate samples mRNA expression level of PVT1
increased with the presence of the risk allele at rs378854
(p = 0.025) (Figure 4). The trend was similar for individuals of
European-American and African-American origin, even though
the frequency of the risk G allele was 0.66 in Europeans and 0.90
in African-Americans (data not shown). As PVT1 is located in a
region of frequent genomic amplification, we examined copy-
number variation (CNV) for intron 1 of PVT1 on DNA from all
tissue samples used for expression studies. PVT1 CNV was not
significantly associated with PVT1 mRNA expression and the
association for rs378854 was not affected by the CNV adjustment
(Figure S8). At the same time, there was no evidence for
association between MYC expression and rs378854 in these
samples (p = 0.274). While this analysis will have to be repeated
in larger sample sets, our results are consistent with a model in
which disruption of YY1 binding at the common risk allele of
rs378854 is associated with transcriptional activation of PVT1. We
also examined expression of miRNAs embedded within the PVT1
locus (hsa-mir-1204, hsa-mir-1205, hsa-mir-1206, hsa-mir-1207-
3p and hsa-mir-1207-5p), but the expression was found to be very
low or undetectable in both normal and tumour prostate samples
and no clear pattern of association emerged (data not shown).
However, we found hsa-mir-1208, located 50 kb downstream of
PVT1, to be expressed in all prostate samples tested. In samples
homozygous for the risk allele the expression was borderline
increased in normal samples (n = 58, p = 0.042), while being
decreased in tumour samples (n = 17, p = 0.068), demonstrating
significant interaction effect for hsa-mir-1208 expression depen-
dent on tissue status (normal/tumour) and rs378854 genotype
(n = 75, p_int = 0.020, Figure S9). Similar analysis of hsa-mir-1208
expression in relation to previously reported rs6983267 did not
reveal any significant associations in sets of normal and tumour
samples, and in interaction (data not shown). The role of hsa-mir-
1208 expression in prostate cancer and its long-distance regulation
by rs378854 warrant further studies. In summary, we observe both
a physical interaction between the risk SNP rs378854 and the
PVT1 promoter and an association between genotype and PVT1
expression.
Discussion
We describe here the identification of a novel transcriptional
regulator element within the 8q24 region that is associated with
expression of PVT1. The risk region is marked by a strong DHS in
breast cancer MCF-7 cells and is able to interact physically with both
theMYC and the PVT1 promoter, but only PVT1 and notMYC gene
expression correlates with the presence of the risk allele. Within the S-
DHS we identify rs378854 as a functional variant for prostate cancer
susceptibility. We demonstrate that, when tested in vitro, using nuclear
extracts from breast and prostate cancer cell lines, the YY1 protein
was able to bind the non-risk allele (G) of 378854, a perfect proxy for
the initially reported prostate cancer signal rs620861 [3,6], more
strongly than the risk allele. However, when tested in vivo, occupancy
by YY1 was only observed in a prostate cancer cell line (1542-CP) but
not in a breast cancer cell line (MCF-7) raising the possibility that the
presence of YY1 prevents the establishment of a DHS. YY1, a zinc-
finger transcription factor, is known to interact with chromatin
remodelling enzymes which are thought to mediate some of YY1’s
functions [22]. Furthermore we observed that, in the context of the S-
DHS, the protective allele of rs378854 was able to repress
transcription in the prostate cell line PC3, but not in breast cancer
MCF-7 cells. Therefore, we suggest that differential binding of YY1
to the prostate-cancer associated variant rs378854 might be
functionally important for the regulation of MYC and/or PVT1
expression. WhileMYC expression was not associated with rs378854,
PVT1 expression did correlate with the presence of the risk allele of
rs378854 (p=0.025). The absence of an association between MYC
expression and the risk genotype may indicate that either the physical
interaction between the risk region and the MYC promoter is
functionally less important or secondary to the effect of PVT1, or that
MYC expression is subject to additional control mechanisms, such as
cell cycle or developmental regulation, which may mask the
underlying association.
With respect to clinical prognosis, it is interesting to note that lower
expression of nuclear YY1 correlates with a poorer outcome for
prostate cancer [30], with the data suggesting that decreased YY1
levels give metastatic cells a survival advantage. YY1 has been
reported to control many aspects of cancer biology through its
interaction with cell cycle genes, association with p53 and other
oncogenes as well as its regulation of key apoptosis-related molecules
[28]. Furthermore, YY1 expression may play a role in both sensitivity
and resistance to chemo- and immunotherapy [28].
Although risk intervals at 8q24 can affect the development of
many different cancer types, it is striking that individual risk loci
Figure 4. Association of PVT1 gene expression with rs378854
genotype in 59 normal prostate samples. P-values are for
univariate linear regression analysis of PVT1 expression in relation to
0, 1 and 2 risk allele (G) of rs378854, adjusted for race. Expression values
are shown on log2 scale relative to a mean value of all samples.
Expression is lowest in carriers of non-risk AA genotypes and highest in
carriers of risk GG genotypes. Mean expression values of each group are
shown as bars.
doi:10.1371/journal.pgen.1002165.g004
Analysis of Prostate Cancer Risk Region at 8q24
PLoS Genetics | www.plosgenetics.org 6 July 2011 | Volume 7 | Issue 7 | e1002165
predispose to only a specific type of cancer. We observe that the
enhancer identified within the colon/prostate/ovarian suscepti-
bility region (rs696983267, shown in red in Figure S1) maps to a
DHS in the prostate and colon, but not in the breast cancer cell
lines analysed (Figure S10). However, the situation for the risk
SNP we examine here is more complicated. We describe a DHS
likely to mark a transcriptional enhancer in breast cancer cell lines,
but suggest that a SNP lying within this element increases
susceptibility to prostate cancer. We find that the YY1 site
overlapping the risk SNP is occupied in a prostate but not a breast
cancer cell line and propose that this binding of YY1 in prostate
cells mediates transcriptional repression that is influenced by the
presence of the SNP. Figure 5 depicts our model of action of
rs378854 in the different cell lines. Interestingly, binding of YY1
does not appear to cause the formation of a DHS in the prostate
cell lines. The available ENCODE data suggests that the majority
of transcription factors bind to open chromatin. However, there is
precedent for transcription factor binding to regions of closed
chromatin. For example, approximately 40% of genome-wide
FOXA1 binding sites map to regions of closed chromatin, where
presumably the factor can exert changes in the chromatin
structure in response to cell signalling or developmental cues
[31]. For many transcription factors, including YY1, the
correlation between site occupancy and chromatin accessibility
has not yet been examined. Furthermore, the S-DHS is clearly
subject to regulation since we detect it only in breast cancer cell
lines. Histone modification data (UCSC genome browser) suggests
that this region may also be accessible in human embryonic stem
cells. In contrast, the majority of DHS elements are accessible
across different tissue types. The regulatory elements in the 8q24
desert are clearly highly complex, tissue-specific and may be
affected by the presence of SNPs. Here we have indentified one
such variant, rs378854, but additional variants and other
mechanisms, such as chromosome amplification and/or rare
variants, may also contribute to cancer risk.
Previous experiments have implicatedMYC as the target gene of
the 8q24 susceptibility region [14–16,18,19]. However, in many
primary tissue samples examined the presence of the risk allele
does not affect MYC expression [18,19]. Using allelic expression it
has been possible to establish such a correlation, but only for some
colon cancer cell lines [20]. Here we present evidence that one of
the 8q24 risk loci for prostate cancer is able to interact with the
promoter of PVT1 and that the presence of the risk allele correlates
with increased PVT1 gene expression in normal prostate tissue.
The PVT1 gene encodes a non-coding transcript implicated in
tumourigenesis [32,33]. PVT1 was identified as a locus co-
amplified with MYC in human Burkitt’s lymphomas and found
to be a MYC activator [34]. In fact, we observed significant
correlation between MYC and PVT1 expression, r2 = 0.54
(p = 0.021 in 18 prostate tumours) and r2 = 0.34 (p= 0.0073 in
59 normal prostates). Therefore, the cancer-associated variants
might eventually affect MYC expression, but indirectly, through
PVT1. Furthermore, miRNAs encoded within PVT1 may regulate
MYC expression either directly or indirectly, by regulating factors
that activate MYC [11]. However, the expression of these miRNAs
appears to be low or undetectable in normal and tumour prostate
tissue samples. On the other hand, a miRNA located 50 kb
downstream of PVT1, hsa-mir-1208, showed an interesting pattern
of expression and interaction between sample status (normal/
tumour) and genotype of rs378854. This interesting association
warrants further studies. Biochemical analysis of the PVT1
promoter suggests that it is a target gene of MYC [35].
Importantly, silencing of PVT1 transcripts activates apoptosis in
cell lines with PVT1 amplifications, while silencing of MYC in the
same cell lines has no effect, suggesting that PVT1 may play a
direct role in tumourigenesis that is independent of MYC [10]. In
this respect, it is interesting to note that PVT1 shows increased
expression in prostate cell lines compared to normal prostate tissue
[17]. Furthermore, genetic variants within PVT1 have been
associated with Hodgkin’s lymphoma [36].
It is striking that the S-DHS element potentially exerts its effect
over large genomic distances, being located approximately 420 kb
and 480 kb from the MYC and PVT1 promoters, respectively.
There are two large ‘‘gene deserts’’ upstream and downstream of
the MYC-PVT1 gene cluster (Figure S11), both containing
extensive sequence conservation as well as multiple cancer
predisposition loci, suggesting that these gene deserts are in fact
highly complex regulatory regions of DNA, as supported by recent
findings of multiple prostate enhancer elements within the MYC
upstream region [17]. The identification of the repressor protein
YY1 as a mediator of protection from cancer susceptibility is a step
towards a better understanding of the function of this genomic
region.
Materials and Methods
Ethics
Anonymised tumour and normal adjacent to tumour prostate
tissue samples were either received from the National Cancer
Institute (NCI) Cooperative Prostate Cancer Tissue Resource
(CPCTR) or from the University of Maryland under protocols
reviewed and approved by Institutional Review Boards.
Cell culture
Breast cancer cell lines MCF-7, MDA-MB-134 (also referred to
as MDA134), PMC42, T47D, normal-like breast cell line HB2,
prostate cancer cell lines PC3 and 1542-CP, normal-like prostate
cell line RWPE-1 and the HCT116 colon cancer cell line were
from the Cambridge Research Institute culture collection. T47D,
MDA134, PMC42, PC3 and HCT116 were maintained in RPMI,
10% foetal calf serum (FCS) and antibiotics; MCF-7 and HB2 in
Figure 5. Schematic representation of the mode of action of
rs378854. In a breast cancer cell line rs378854 is not bound by YY1
(site shown as empty blue circle) and the DHS present in this region is
likely to act as a transcriptional regulator. In contrast, in a prostate
cancer cell line YY1 binds (filled blue circle) and represses transcription
of a target gene. The level of repression is influenced by the presence of
the SNP in the YY1 binding site. Small boxes represent multiple other
regulatory elements known to exist in the region.
doi:10.1371/journal.pgen.1002165.g005
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DMEM, 10% FCS and antibiotics, but HB2 cell medium was
supplemented with insulin (5 mg/ml) and hydrocortisone (1 mg/
ml) (Sigma, UK). RWPE-1 cells were cultured in Keratinocyte
Serum Free Medium (Gibco) and supplemented with 5 ng/ml
human recombinant EGF and 0.05 mg/ml bovine pituitary
extract (both from Sigma). 1542-CP cells were cultured in
keratinocyte serum-free medium (Keratinocyte-SFM, Life Tech-
nologies, Grand Island, NY) containing 25 mg/ml bovine pituitary
extract, 5 ng/ml epidermal growth factor, 2 mM L-glutamine,
10 mM HEPES buffer, antibiotics, and 5% heat-inactivated FCS.
DNase I hypersensitivity assay
Nuclei of all cell lines were harvested and digested with DNase I
as previously described [22]. For the DNase-seq experiment DNA
from DNase-digested nuclei was isolated by standard procedures,
separated on a 1.4% agarose gel and gel-purified DNA fragments
between 125 and 500 bp were used directly in Illumina pre-
amplification. The amplified library was again resolved on an
agarose gel to select 200–300 bp fragments that were gel-purified
and sequenced using an Illumina Genome Analyser II, according
to manufacturer’s instructions. MCF-7 DNase-seq was carried out
as part of our analysis of ER responses. Multiple MCF-7 aliquots
were transfected with and without a siRNA to GATA3, but no
differences in the DHS profile were detected. BWA software [37]
was used for sequence alignment by the CRI Bioinformatics core
facility. A representative experiment with low background is
shown. Two independent DNase-seq experiments for PC3 and
RWPE-1 gave very similar results and again a representative
example is shown. Sequence reads were displayed on the UCSC
genome browser. The presence of the S-DHS DNase-seq peak was
verified in T47D cells (Figure S4). For DNase-chip the generation
of libraries of DNase hypersensitive fragments has previously been
described [22]. Libraries were hybridised to Agilent custom tiling
arrays covering 2Mb at 8q24.
Chromatin conformation capture (3C)
The 3C method [38] was applied to detect physical interactions
between genomic regions (such as between promoters and distant
enhancers [39]) using a sequence of interest (bait) from 8q24 region.
The experimental procedure for this technique is outlined in Figure
S12. The 3C experiments were carried out in the normal-like cell
lines HB2 and RWPE-1 as many cancer cell lines such as PC3 and
MCF-7 carry amplifications across the 8q24 region [9,10]. Briefly,
exponentially growing cells were cross-linked with 1% formaldehyde
for 10 min at room temperature, washed 3x with cold PBS and
scraped into microcentrifuge tubes. Cells were spun at 3000 rpm for
5 mins and resuspended in 1 ml lysis buffer (50 mM Tris-HCl
pH 8.0, 1% SDS, 10 mM EDTA). After 10 min cells were
centrifuged and resuspended in lysis buffer supplemented with
0.4% NP-40 and 1.8% Triton-X. After centrifugation for 20 seconds
at full speed 1.56106 nuclei were resuspended in 300 ml EcoRI
digestion buffer and 1.8% Triton-X. Nuclei were incubated for 45
minutes at 37uC in a cell shaker and subsequently digested with
1000 U EcoRI (NEB) overnight. The enzyme was heat-inactivated
and the sample diluted in 1 ml. Ligation was carried out overnight
using 4000 U T4 ligase at 16uC. A second digestion step was carried
out using 1000 U BamHI (NEB). Genomic DNA was purified after
proteinase K treatment using standard protocols. PCRs were carried
out using Power SYBR Green Mastermix (Applied Biosystems),
100 ng template DNA, 5 pmol of each primer in a volume of 20 ml
(initial 95uC denaturation step, then 1 min at 60uC and 20 secs at
92uC for 40 cycles). Products were separated on a 3% NuSieve
agarose gel. The identity of all PCR products was verified by direct
sequencing of PCR products.
Electrophoretic mobility shift assay (EMSA)
EMSAs were carried out as previously described [40].
Oligonucleotide sequences used in the assays are provided in
Table S1. Antibodies for supershifts were obtained from Santa
Cruz Biotech: aYY1 (sc1703x), aC/EBPa (sc9314x), aSP1
(sc14027x) and aOct-1 (sc232x) and 2 ml were used per reaction.
Chromatin Immunoprecipitation (ChIPs)
ChIP reactions were carried out as described by Schmidt et al.
[41] using 10 mg aYY1 (sc7341x, Santa Cruz Biotech). DNA was
purified from the precipitates and used in RT-PCR reactions with
primers listed in Table S1. Primer design was carried out using the
UCSC genome browser mapability plot (Figure S3B) in conjunc-
tion with Primer 3 software. The primer pairs used gave rise to a
single reproducible band whose identity was confirmed by
sequencing. The RT-PCR protocol includes a dissociation step
to confirm that the reaction gave rise to only a single product.
Results were normalised against input and normal mouse IgG
(sc2025, Santa Cruz Biotech). As positive control the promoter
region of the glucocorticoid receptor [42] was chosen, as this
contains three YY1 sites. Results are given relative to S-DHS-ve, a
sequence 5 kb upstream of the S-DHS which we have shown to be
in inaccessible chromatin (Figure 1). 1542-CP cells and MCF-7
cells are heterozygous for the risk SNP rs378854. Consistent results
were obtained in three biological repeats. Error bars denote the
technical error in a representative experiment.
Cloning and transfection
S-DHS_cloning-forward and reverse primers (Table S1) were used
to amplify a DNA fragment from genomic DNA of PMC42 breast
cancer cell line (heterozygous for rs378854) and cloned using the
TopoTA cloning system (Invitrogen). Plasmids were sequenced and
clones carrying either the minor or the common allele of rs378854
were selected. The inserts were excised using SalI and BamHI
(resulting fragment: chr8:128,392,958-128,393,353) and cloned into
pGL3-basic or pGL3-enhancer vector (Promega), cut with XhoI and
BglII. The same fragments were inserted into pGL3-promoter vector
(Promega) cut with BamHI and SalI. Plasmids were prepared with an
endotoxin-free kit (Qiagen) and transiently transfected into PC3 and
MCF-7 cells grown in 24 well plates. 0.5 mg reporter plasmid and
0.1 mg b-galactoside transfection control plasmid in 30 ml OptiMEM
(Gibco) were incubated for 20 min with 4.5 ml Fugene (Roche) before
being added to 50% confluent wells. 10% FCS was added after
2 hours. Cells were harvested in 100 ml lysis buffer after 24 hours and
luciferase and b-galatosidase activity was assayed using Promega kits.
The data is averaged from two independent transfection experiments,
each carried out in triplicate.
Ethics statement and clinical data
Anonymised tumour and normal adjacent to tumour prostate
tissue samples were either received from the National Cancer
Institute (NCI) Cooperative Prostate Cancer Tissue Resource
(CPCTR) or from the University of Maryland under protocols
reviewed and approved by Institutional Review Boards. We also
obtained clinical information including age at diagnosis, race,
Gleason score and PSA level at diagnosis.
Analysis of gene expression in prostate samples
The frozen samples were homogenized with Tissue Lyser
(Qiagen) and divided into two fractions from which total RNA was
prepared with MirVana kit (Applied Biosystems) and DNA was
prepared with Gentra (Qiagen). The integrity of RNA was
confirmed by Bioanalyzer (Agilent).
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mRNA expression analysis
cDNA was prepared from 800 ng of total RNA with Superscript
III kit and random hexamers (Invitrogen). All expression assays
were first evaluated in pooled prostate cDNA samples containing
25 ng, 5 ng, or 1 ng of total RNA per reaction. Genomic DNA
and water were used as negative controls for each assay. Based on
this test, endogenous controls Beta-2 microglobulin (B2M, assay
HS_00187842_m1), Cyclophilin (PPIA, assay 4326316E) and MYC
expression (assay Hs00905030) were tested using 5 ng of total
RNA per reaction, while PVT1 expression (assay Hs00413039) was
evaluated with 20 ng of total RNA per reaction. Expression of
alternative splicing forms of PVT1 measured by assay Hs01069044
was beyond confident detection level even with 20 ng of total
RNA and was not used on individual tissue samples.
The expression was tested in 4 technical replicates for each
sample and assay, technical replicates were averaged and standard
deviations were determined.
miRNA expression
TaqMan miRNA expression assays for target miRNAs from PVT1
gene (002872 for hsa-miR-1204, 002778 for hsa-miR-1205, 002878
for hsa-miR-1206, 002826 for hsa-miR-1207-3p, 241060-mat for
hsa-miR-1207-5p, 002880 for hsa-mir-1208) and 3 endogenous
controls (001973 for U6 snRNA, 001094 for RNU44 and 001006 for
RNU48) as well as other reagents for miRNA expression were
purchased from Applied Biosystems. cDNA was prepared from
experimentally determined amount of total RNA with TaqMan
MicroRNA reverse transcription kit. All assays were first tested on
pooled cDNA samples using 10, 20 and 100 ng of total RNA per
reaction as input. Based on this test, U6, RNU44 and RNU48 assays
were run on all individual prostate samples starting from 20 ng of
total RNA per reaction. For hsa-miR-1204, 1205, 1206 and 1207-3p
reactions were run starting from 100 ng of total RNA per reaction.
Expression of hsa-miR-1207-5p was below detection level and was
not tested further. All expression assays were run in technical
duplicates and target assays were normalized by a geometric mean of
U6, RNU44 and RNU48.
CNV analysis in PVT1 region
A custom-designed assay was used to quantify copy number
variation (CNV) within intron 1 of PVT1 gene (PVT1-CNV-F and
PVT1-CNV-R, 173 bp) (Table S1). The assay was run on DNA
prepared from the prostate tissue samples with 5 ng of DNA, 2x
Power SYBR Green master mix (Applied Biosystems) and primers.
The results were normalized to copy number of control RNaseP
assay quantified in the same DNA samples. All assays were run in
four technical replicates on 7900 Sequence Detection System
(Applied Biosystems).
Statistical analysis
Statistical significance of differences in the reporter assays was
determined using a Student’s two-sided t-test with a Bonferroni
correction for multiple comparisons. The expression values of
mRNA and miRNA target assays were normalized by corre-
sponding endogenous controls according to dCt method of relative
quantification and tested for normality of distribution. Univariate
linear regression was used to analyze expression values in relation
to 0, 1 or 2 copies of risk alleles of rs378854. Age, race and PVT1-
CNV values were tested as possible covariates but were found to
have no significant effect. The analysis was performed with SPSS
16.0. Normalized expression values were centered to the mean of
the samples heterozygous for rs378854 and plotted with GraphPad
Prism5 software.
Supporting Information
Figure S1 Map of the haplotype blocks (http://hapmap.ncbi.
nlm.nih.gov) extending from the FAM84B to the MYC gene.
Haplotype blocks that are associated with cancer are highlighted
in colour. There are eight prostate cancer-associated loci (blue),
one associated with prostate, colorectal and ovarian cancer (red)
and one each for lymphoma (orange), breast cancer (green) and
bladder cancer (purple). The position of two most strongly cancer-
associated SNPs in the breast and prostate cancer risk locus
examined in this study are shown by arrows.
(PPT)
Figure S2 Comparison of DNase I hypersensitivity of the 8q24
locus using Illumina sequencing (DNase-seq) for MCF-7 cells
versus analysis by hybridisation to microarrays (DNase-chip). The
‘‘breast’’ lane gives probability plots for the average values
obtained using independent hybridisation of duplicates of three
different breast cancer cell lines: MCF-7, T47D and PMC42.
Microarray data was normalised and analysed by the ACME
algorithm and combined probability plots are shown. 95% cut-offs
and a sliding window of 500 bp were used. A 100 kb window
overlapping (A) the breast cancer susceptibility region and (B) the
MYC and PVT1 promoters is shown. Some peaks such as the S-
DHS overlap repetitive elements and are not apparent in the
microarray analysis since repetitive sequences are not tiled
(indicated by red arrows). Peaks that are apparent in microarray
but not sequencing experiments are most likely due to cross-
hybridisation with non-specific sequences on the microarray
(exemplified by a blue arrow).
(PPT)
Figure S3 Examination of DNase-seq data for the region
surrounding the S-DHS. (A) The DNase-seq tracks for chr8:
128,380,00–128,411,500 are shown for two independent experi-
ments for each cell line examined, denoted a and b in each case.
For each experiment the number of reads was adjusted to the total
number of reads obtained in the experiment. The regions shown
includes all SNPs with an r2.0.8 for rs620861 (see Figure S6). (B)
DNase-seq tracks derived with two different stringency settings
within the BWA software (map01 and map15) for MCF-7 and
RWPE-1 for the LINE element that contains the S-DHS are
shown. As the S-DHS maps to a LINE element, correct alignment
of sequence reads to the reference genome is of critical
importance. We therefore tested different stringency values in
the alignment algorithms, but found that even when alignments of
sequence reads are called with a confidence greater than 97%
(map15), MCF-7 displays a strong signal. The LINE element
overlapping the S-DHS contains sufficient information to allow
unique assignment of sequence reads as indicated by the
‘‘mapability track’’ on the UCSC genome browser. This track
(Duke uniqueness for 35 bp) depicts those regions in the genome
where unique alignments of sequence reads to the reference
genome are possible, allowing for 2 mismatches. The alignment
peaks in the sequencing track are wider than those in the
mapability track since 44mers were determined in the Illumina
sequencing. When shorter oligomers are examined (Umass
Uniq15) fewer of the peaks can be uniquely assigned to the
reference genome. The LINE element is not marked by the
ENCODE artefacts track, suggesting that standard sequence
alignment algorithms can be used for these regions. The ‘‘Human
Chained Self Alignments’’-track indicates that the LINE element
under investigation self chains only to a single LINE element on
chromosome 3.
(PPT)
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Figure S4 Analysis of properties of the two highly homologous
LINE elements on chromosome 8 (overlapping the S-DHS) and
chromosome 3. DHS-seq tracks for MCF-7 and RWPE-1,
mapped with an alignment stringency of 15, are shown for (A)
chr8: 128,392,900–128,396,800 and (B) chr3: 11,505,153–
11,509,023. The sequences on chromosome 3 are shown in the
opposite direction with respect to the reference genome. The
highly similar LINE element on chromosome 3 also shows some
DNase I hypersensitivity in MCF-7 cells, but the signal is 3-fold
lower, making it highly unlikely that the S-DHS observed on
chromosome 8 is due to a ‘‘spill-over’’ of sequence read alignments
from chromosome 3.
(PPT)
Figure S5 Chromatin immunoprecipitation (ChIP) assay for the
breast and prostate cancer susceptibility region in MCF-7 cells. All
experiments were carried out by ChIP-seq [24] and results are
shown for the two cohesin subunits Rad21 and SA1, CTCF and
FoxA1. The peaks obtained overlap with the S-DHS identified
here. (A) depicts the breast cancer susceptibility region
(chr8:128,380,000–128,460,000), while (B) shows an enlarged
view of the S-DHS. Each panel also shows UCSC mapability plots
(Duke Unique 35) and repeat elements across the region. As for
the DNase-seq, alignment peaks occur only at those sequences that
are sufficiently unique to allow mapping to the genome.
Unmappable regions between peaks may be occupied, but short
read sequencing is not informative for these regions.
(PPT)
Figure S6 The haplotype block encompassing both the prostate
and breast cancer susceptibility hits is shown. Blue arrows
correspond to the 14 variants that are correlated with rs620861,
the top hit identified by Al Olama et al. [3] at r2.0.8. Green
arrows highlight the variants strongly correlated with rs13281615,
the top hit for breast cancer susceptibility [2], again at r2.0.8. The
two sets of SNPs cluster to different region of the haplotype block.
(PPT)
Figure S7 (A) DNase-seq trace for MCF-7 and T47D of a 1.2 kb
fragment overlapping the S-DHS. The position of rs378854 and
the relative position of the fragment used in functional assays are
shown. (B) SNPs identified within this 1.2 kb fragment. Chromo-
some position, minor allele frequency (MAF), alleles and
correlation to the top hit prostate cancer SNP rs620861 are given.
(PPT)
Figure S8 Analysis of copy number variation (CNV) within the
PVT1 region. (A) The mean values and 95% confidence intervals
for PVT1_CNV normalized by RNAseP values are given for groups
of normal and tumour prostate tissue samples. CNV_PVT1 values
for each sample were calculated as CNV = Ct (RNAseP) –Ct
(PVT1); each Ct value was measured in 4 technical replicates and
plotted on a Log2 scale. Ct - is a PCR cycle of detection of the
signal by qPCR. First, we tested if PVT1_CNV was different in
normal and tumor samples, but detected no significant difference
(p = 0.849). (B) PVT1 mRNA expression after adjustment by
PVT1_CNV and in relation to the number of risk alleles of
rs378854 in 53 normal prostate tissue samples for which both
mRNA expression and PVT1_CNV information was available. The
PVT1_CNV did not significantly affect the results for PVT1
mRNA expression: effect of PVT1_CNV, p = 0.708; effect of
rs378854, p = 0.047 (adjusted for PVT1_CNV); effect of rs378854,
p = 0.025 (not adjusted for PVT1_CNV, in 59 normal prostate
samples). Thus, the effect of rs378854 remains significant
(p = 0.047) even after adjustment by PVT1_CNV values.
(PPT)
Figure S9 Quantitative expression for hsa-mir-1208 in normal
and tumour prostate tissue samples. The expression has been
normalized by a geometric mean of U6, RNU44 and RNU48
endogenous controls and is presented in log2 scale. The expression
in carriers of 0 or 1 risk alleles of rs378854 is comparable in
normal and tumour tissue samples, while in samples homozygous
for risk allele, the expression is increased in normal samples while
it’s decreased in tumours, providing a significant interaction effect
(p = 0.020).
(PPT)
Figure S10 Chromatin accessibility of the 1 kb region (chr8:
128,482,000–128,483,000) containing the colon and prostate-
specific enhancer marked by rs6983267 (chr8: 128,482,487).
DNase-chip data are shown for three breast cancer cell lines
(MCF-7, T47D and PMC42= breast), two prostate cell lines
(LnCap and RWPE-1= prostate) and the HCT116 ( = colon) cell
line. Microarray data was normalised and analysed by the ACME
algorithm and combined probability plots are shown. 95% cut-offs
and a sliding window of 500 bp were used in the ACME
algorithm.
(PPT)
Figure S11 Cartoon showing the cancer predisposition loci in a
3.2 Mb genomic interval on 8q24, spanning the nearest expressed
neighbours of the MYC and PVT1 genes. Grey boxes depict
RefSeq genes, with light grey indicating no expression in prostate
cells. Ovals depict cancer predisposition hits with tissue subtypes as
indicated by the colours (UCSC genome browser and [36]).
(PPT)
Figure S12 Carto on of Chromatin Conformation Assay.
(PPT)
Table S1 Oligonucleotides used in this study.
(DOC)
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